Jivi Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to frequent bleeding episodes in hemophilia a, limitations of standard factor viii therapies, early recombinant factor adoption, focus on joint damage prevention, growth in hemophilia treatment centers.

The growth in the forecast period can be attributed to rising use of long acting clotting factors, increasing access to home infusion, expansion of pediatric hemophilia care, supportive reimbursement policies, innovation in recombinant therapies. Major trends in the forecast period include growing adoption of extended half life factor viii, shift toward prophylactic hemophilia management, reduced injection frequency preferences, expansion of home based hemophilia care, improved patient adherence to therapy.

The rising prevalence of hemophilia is expected to drive the growth of the jivi market in the future. Hemophilia is caused by genetic mutations in the X-linked genes that are responsible for producing clotting factors, resulting in insufficient or defective factors VIII (hemophilia A) or IX (hemophilia B), which hinders the blood's ability to clot effectively. The increasing prevalence of hemophilia is due to better diagnostic capabilities, increased awareness, and more widespread reporting of cases worldwide. Jivi addresses this by replacing the deficient Factor VIII with a long-acting recombinant therapy, helping blood clot and prevent or control bleeding episodes. Its extended half-life reduces the frequency of dosing, enhancing patient convenience and adherence. For example, in April 2025, Hemophilia News Today, a U.S.-based medical news platform, reported that the estimated number of individuals living with hemophilia globally had reached approximately 836,000, including about 284,000 individuals with the severe form of the disorder. Therefore, the growing prevalence of hemophilia is contributing to the growth of the jivi market.

The growing emphasis on personalized medicine is expected to drive the expansion of the jivi market in the future. Personalized medicine is a healthcare approach that tailors treatments and therapies to an individual's genetic makeup, environment, and lifestyle. The demand for personalized medicine is fueled by several factors, including advancements in genomic medicine, the rising incidence of chronic diseases, better diagnostic tools, and a more patient-centered healthcare model. Jivi plays a role in personalized medicine by offering customized treatment for hemophilia A patients, as its extended half-life enables personalized dosing schedules based on individual patient needs, improving adherence and reducing bleeding episodes. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from six in 2022. Consequently, the growing focus on personalized medicine is contributing to the growth of the jivi market.

An increase in research and development investments is anticipated to further accelerate the growth of the jivi market. Such investments stem from the need for innovative therapies that address unmet medical needs, improve treatment efficacy, and enhance patient outcomes across various therapeutic areas. In the case of Jivi, these investments focus on improving its efficacy, safety, and convenience by enhancing its extended half-life, reducing dosing frequency, and increasing patient adherence, while also supporting the advancement of personalized medicine for more tailored treatment options. For instance, in December 2024, Focus2030, a France-based civil society organization, highlighted that Gavi's 2026-2030 Investment Opportunity calls for $9 billion in funding, including $1.7 billion for the International Finance Facility for Immunization, to immunize an additional 500 million children by 2030, ultimately saving 8 to 9 million lives. As a result, rising research and development investments are boosting the growth of the jivi market.

Major companies operating in the jivi market are Bayer AG.

North America was the largest region in the jivi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jivi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the jivi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the jivi market by increasing costs associated with recombinant protein manufacturing inputs, specialized bioprocessing equipment, and cold chain distribution. These impacts are more evident in hospital and home healthcare channels across import dependent regions such as asia pacific. Higher costs can affect procurement planning and therapy affordability. At the same time, tariffs are encouraging localized biologics production and strengthening regional supply resilience for hemophilia treatments.

The jivi market research report is one of a series of new reports that provides jivi market statistics, including jivi industry global market size, regional shares, competitors with a jivi market share, detailed jivi market segments, market trends and opportunities, and any further data you may need to thrive in the jivi industry. This jivi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Jivi is a recombinant factor VIII (antihemophilic factor) medication used to treat and prevent bleeding episodes in individuals with hemophilia A, a genetic blood-clotting disorder. It works by replacing the missing Factor VIII protein, which is essential for blood clotting, helping to reduce the frequency of bleeding episodes when used as part of a prophylactic regimen. Jivi is notable for its extended half-life, allowing for fewer injections compared to traditional Factor VIII therapies, thereby enhancing patient convenience and improving adherence.

The primary formulations available in the Jivi market are lyophilized powder for reconstitution and ready-to-use formulations. Jivi lyophilized powder for reconstitution is a freeze-dried form of the therapy that is reconstituted with a solvent before administration. Jivi is available for both intravenous and subcutaneous routes of administration. The product is used for various indications, including treating hemophilia A, providing prophylaxis, and offering on-demand treatment for bleeding episodes. Distribution of Jivi occurs through direct sales, wholesalers, distributors, and retail pharmacies. The key end-use settings for Jivi include hospitals, hemophilia treatment centers, specialty clinics, and home healthcare environments.

The jivi market consists of sales of prophylactic dosing regimens and injectable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.